Jazz Pharma to Pay $145 Million to Settle Narcolepsy Drug Antitrust Case
Insurance Journal - Apr 09, 2025
Jazz Pharmaceuticals JAZZ.O said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem. Xyrem, a medication approved in the U.S., is used for the …...
Recommended Articles
Posted: Apr 18, 2025
Uber Technologies Inc. is spending six figures on advertisements in New York in its latest appeal to...
Posted: Apr 18, 2025
USI Insurance Services, one of the largest brokerages in the country, has filed suit against a forme...
Posted: Apr 18, 2025
A federal judge on Tuesday issued a preliminary injunction that prevents the U.S. Department of Labo...